Replies to post #151312 on Biotech Values

[jq1234]

Even all 18% are from T315I, it doesn't mean these are overlapping patients. Ponatinib MCyR in T315I is about 70%. To me, it is more likely different patients respond to the two drugs than exactly same patients.